Skip to Content

Revatio Approval History

  • FDA approved: Yes (First approved June 3rd, 2005)
  • Brand name: Revatio
  • Generic name: sildenafil citrate
  • Company: Pfizer Inc.
  • Treatment for: Pulmonary Hypertension

Revatio (sildenafil) is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension.

Development History and FDA Approval Process for Revatio

Nov 20, 2009Approval FDA Approves Intravenous Formulation Of Pfizer's Revatio (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Jun  3, 2005Approval Revatio Pfizer Inc. - Treatment for Pulmonary Arterial Hypertension
Dec  3, 2004Pfizer Submits Regulatory Filings for Revatio as a Treatment for Pulmonary Arterial Hypertension

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.